Ipilimumab + Nivolumab + Nogapendekin for Lung Cancer

(FLINN Trial)

This trial tests a new combination of drugs for advanced non-small cell lung cancer. The researchers aim to determine if adding nogapendekin alfa inbakicept (an experimental treatment) to existing treatments, nivolumab and ipilimumab, can extend the time patients live without cancer progression. Individuals with untreated or recurring stage IV lung cancer might be suitable candidates, particularly if they have not recently received certain treatments. The trial seeks to demonstrate that this new combination is safe and more effective than previous treatments. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you need to stop taking your current medications. However, if you are on high doses of corticosteroids or certain immunosuppressive drugs, you may not be eligible to participate.

Research shows that the combination of ipilimumab, nivolumab, and nogapendekin alfa inbakicept is expected to be safe and well-tolerated. In earlier studies, patients who took these drugs showed improvements in their immune system, particularly an increase in lymphocytes, a type of white blood cell. This suggests the combination might help fight lung cancer.

Ipilimumab and nivolumab are already approved for other uses, indicating they have been thoroughly studied and their safety is well understood. While nogapendekin alfa inbakicept is newer, it has been tested with other treatments and has shown promising safety results.

Researchers are excited about this treatment combination for lung cancer because it uniquely combines three different therapies: ipilimumab, nivolumab, and nogapendekin alfa inbakicept. Unlike traditional treatments that often focus on chemotherapy, this regimen uses immune checkpoint inhibitors (ipilimumab and nivolumab) to help the immune system recognize and attack cancer cells. Additionally, nogapendekin alfa inbakicept (N-803) is a novel agent designed to enhance immune response further, offering a new mechanism of action that could improve outcomes. This combination approach has the potential to provide a more robust and sustained attack on cancer cells, making it a promising option in the fight against lung cancer.

Research has shown that using ipilimumab and nivolumab together helps the immune system fight cancer more effectively. These drugs have shown promise in treating non-small cell lung cancer (NSCLC) by blocking proteins that prevent the immune system from attacking cancer cells. In this trial, participants will receive a combination of ipilimumab, nivolumab, and nogapendekin alfa inbakicept to determine if it can further enhance the immune response. Early results with similar drug combinations suggest better outcomes in progression-free survival, meaning the cancer doesn't worsen as quickly. This combination is being tested to see if it can outperform past treatments that used only ipilimumab and nivolumab.¹³⁴⁶⁷